# Special Issue

# Molecular Pathogenesis and Therapeutic Breakthroughs in Cutaneous Malignancies: From Melanoma to Lymphoma

## Message from the Guest Editor

Skin cancer is the most common cancer in the United States and worldwide. In the U.S., more than 5 million skin cancers are diagnosed annually, primarily nonmelanoma skin cancers such as basal cell and squamous cell carcinoma. Some of the skin cancers, such as melanoma and Merkel cell carcinoma, are aggressive diseases with 5-year relative survival of cases with distant metastasis as low as 35% and 21%, respectively.

Skin cancer has the highest tumor mutational burden and the highest objective response to immunotherapy (anti-PD-1 or anti-PD-L1 therapy). Numerous targeted therapies targeting known molecular alterations in melanoma have revolutionized its therapy. A better understanding of immunological abnormalities, molecular pathways, biomarkers, and epigenetics of melanoma has brought a paradigm shift in the management and survival of these patients.

The murine model of melanoma has better revealed the tumor immune microenvironment, elucidated the mechanism of PD-L1 depletion-induced cancer cell senescence via strong induction of stimulator of interferon genes (STING) expression, and demonstrated the potential of numerous immunomodulatory drugs.

## Guest Editor

Dr. Dinesh Pradhan

Department of Pathology, Microbiology Immunology and Dermatology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE 68198-3135, USA

## Deadline for manuscript submissions

closed (15 March 2026)

**Cells**

**an Open Access Journal by MDPI**

**Impact Factor 5.2**
**CiteScore 10.5**
**Indexed in PubMed**

mdpi.com/si/254026

*Cells*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

# Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

MDPI

# About the Journal

## Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

## Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).